IRCT20220124053814N1已完成未知
A randomized, parallel-controlled study evaluating the efficacy of a program of group psychodrama interventions based on maladaptive schemas on reducing effects of early maladaptive schemas in adults aged 25 to 45
The University of Tehran0 个研究点目标入组 70 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25 years 至 45 years（—）
- 性别
- All
入选标准
- •Age: Adults aged 25 to 45
- •Employment status: Employing in knowledge-enterprise companies in Tehran
- •Salary: More than 4.5 million tomans per month (This amount has been identified as a median of income in 2020. According to the latest report from the Ministry of cooperatives labour and social Welfare (2021), the income of a three-person household in Tehran for 2020 is estimated to be approximately between 3 and 5 million tomans).
排除标准
- •Psychological disorders, such as: depression or anxiety
研究者
相似试验
进行中（未招募）
1 期
Randomized, parallel controlled study with routine clinical practice to evaluate the efficacy and tolerability of PRFC ENDORET® in the treatment of frontal fibrosing alopecia• Patients diagnosed with fibrosing frontal alopecia (FFA) with an age greater than or equal to 18 years.• Patient not responding to previous treatments for at least 6 months.• Use of effective physical or pharmacological contraceptive measures• Free acceptance to participate in the trial, with the written informed consent of the volunteer.EUCTR2021-000865-33-ESINSTITUTO DE INVESTIGACIÓN SANITARIA BIOARABA74
进行中（未招募）
不适用
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2014-002541-22-GBsanofi-aventis recherche & développement340
进行中（未招募）
1 期
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-ESsanofi-aventis recherche & développement340
进行中（未招募）
1 期
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-DEsanofi-aventis recherche & développement540
进行中（未招募）
1 期
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-HUsanofi-aventis recherche & développement340